SCHEMBL2854889

SCHEMBL2854889

Cc1cc(NS(=O)(=O)c2ccc(C(N)=O)cc2)no1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.70
MAPT P10636 3/20 0.70
ADRA1A P35348 1/20 0.70
TSHR P16473 1/20 0.63
MAPK1 P28482 1/20 0.63
CYP2C9 P11712 2/20 0.61
KMT2A Q03164 3/20 0.60
MEN1 O00255 2/20 0.60
HSP90AA1 P07900 1/20 0.60
HSP90AB1 P08238 1/20 0.60
CYP1A2 P05177 1/20 0.59
CYP2D6 P10635 1/20 0.59
CYP2C19 P33261 1/20 0.59
GBA1 P04062 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
ALOX12 P18054 3/20 0.57
GLA P06280 1/20 0.57
PPIA P62937 1/20 0.57
THRB P10828 1/20 0.57
HPGD P15428 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5565268 0.87 ALDH1A1 (0.68) ALDH1A1MAPTADRA1ATSHRMAPK1
SCHEMBL23440275 0.85 TSHR (0.70) ALDH1A1MAPTADRA1ATSHRMAPK1
Sulfamethoxazole SCHEMBL20456610 0.83 ALDH1A1 (0.89) ALDH1A1MAPTADRA1ATSHRMAPK1
Sulfamethoxazole SCHEMBL4539943 0.83 ALDH1A1 (0.94) ALDH1A1MAPTADRA1ATSHRMAPK1
Sulfamethoxazole SCHEMBL28003342 0.83 ALDH1A1 (0.94) ALDH1A1MAPTADRA1ATSHRMAPK1
SCHEMBL21795038 0.83 KMT2A (0.80) ALDH1A1MAPTCYP2C9KMT2AMEN1
Sulfamethoxazole SCHEMBL6896861 0.82 ALDH1A1 (1.00) ALDH1A1MAPTADRA1ATSHRMAPK1
Sulfamethoxazole SCHEMBL3656 0.82 ALDH1A1 (1.00) ALDH1A1MAPTADRA1ATSHRMAPK1
SCHEMBL31469213 0.82 ALDH1A1 (0.73) ALDH1A1MAPTADRA1ATSHRMAPK1
SCHEMBL12879697 0.82 ALDH1A1 (0.77) ALDH1A1MAPTADRA1ATSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1451160-B1 PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN ICAGEN INC (US) 2010-01-13 EP claimed
EP-1848713-A2 AMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F.HOFFMANN-LA ROCHE AG (CH) 2007-10-31 EP claimed
US-20060116407-A1 Amide derivatives HOFFMANN-LA ROCHE INC. 2006-06-01 US claimed
WO-2006053778-A2 AMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2006-05-26 WO claimed
EP-1451160-B1 PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN ICAGEN INC (US) 2010-01-13 EP disclosed
US-20080064690-A1 PYRAZOLE-AMIDES AND -SULFONAMIDES ICAGEN, INC. (US) 2008-03-13 US disclosed
EP-1848713-A2 AMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F.HOFFMANN-LA ROCHE AG (CH) 2007-10-31 EP disclosed
US-7223782-B2 Pyrazole-amides and -sulfonamides ICAGEN, INC. (US) 2007-05-29 US disclosed
US-20060116407-A1 Amide derivatives HOFFMANN-LA ROCHE INC. 2006-06-01 US disclosed
WO-2006053778-A2 AMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2006-05-26 WO disclosed
US-20050049237-A1 Pyrazole-amides and -sulfonamides ICAGEN, INC. (US) 2005-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064690-A1 PYRAZOLE-AMIDES AND -SULFONAMIDES SCN3A, TRPV3, HCN3 ALDH1A1 3589/4885MAPT 3590/4885ADRA1A 3394/4885
US-20060116407-A1 Amide derivatives GLS, SDHA, GLS2 ALDH1A1 71/4885MAPT 3340/4885ADRA1A 801/4885
US-20050049237-A1 Pyrazole-amides and -sulfonamides SCN3A, TRPV3, HCN3 ALDH1A1 3589/4885MAPT 3590/4885ADRA1A 3394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.